Drug intelligence / Profile preview

drospirenone + ethinyl estradiol + myo-inositol

Development stage
Unknown
Lead developer
Bayer
Modality
Drug Delivery Systems
Administration
Oral
01

Overview

This entry describes a proposed or hypothetical combination of the established oral contraceptive ingredients drospirenone and ethinyl estradiol with myo-inositol. The combination of drospirenone (a progestin) and ethinyl estradiol (an estrogen) is a well-known hormonal contraceptive found in products like Yasmin. Their combined mechanism of action involves: * Suppressing ovulation * Changing cervical mucus to hinder sperm movement * Creating an unfavorable environment for fertilized eggs in the uterus This two-drug combination is also approved for treating premenstrual dysphoric disorder (PMDD) and moderate acne vulgaris. However, the specific combination that includes myo-inositol alongside drospirenone and ethinyl estradiol is *not directly mentioned* or detailed in the provided search results. While myo-inositol is a naturally occurring substance studied for various potential health benefits, its role, specific properties, approved indications, or development status *in this particular three-drug formulation* are not available based on the given information. The typical dosage mentioned for the *two-drug* drospirenone/ethinyl estradiol combination is 3 mg of drospirenone and 0.03 mg of ethinyl estradiol per tablet. Dosage information for the triple combination is not provided.

02

Targets

ESR1 (ERα)PR (Progesterone receptor)ESR2 (ERβ)AR (Adrenergic receptors)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on drospirenone + ethinyl estradiol + myo-inositol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on drospirenone + ethinyl estradiol + myo-inositol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call